Literature DB >> 26328027

Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Fauzia Z Khan1, Ryan B Perumpail1, Robert J Wong1, Aijaz Ahmed1.   

Abstract

An increase in the prevalence of obesity and diabetes mellitus has been associated with the rise in nonalcoholic fatty liver disease (NAFLD). Two-thirds of the obese and diabetic populations are estimated to develop NAFLD. Currently, NAFLD is the most common etiology for chronic liver disease globally. The clinical spectrum of NAFLD ranges from simple steatosis, an accumulation of fat greater than 5% of liver weight, to nonalcoholic steatohepatitis (NASH), a more aggressive form with necroinflammation and fibrosis. Among the patients who develop NASH, up to 20% may advance to cirrhosis and are at risk for complications of end-stage liver disease. One of the major complications observed in patients with NASH-related cirrhosis is hepatocellular carcinoma (HCC), which has emerged as the sixth most common cancer and second leading etiology of cancer-related deaths worldwide. The incidence of HCC in the United States alone has tripled over the last three decades. In addition, emerging data are suggesting that a small proportion of patients with NAFLD may be at higher risk for HCC in the absence of cirrhosis - implicating obesity and diabetes mellitus as potential risk factors for HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Overweight

Year:  2015        PMID: 26328027      PMCID: PMC4550870          DOI: 10.4254/wjh.v7.i18.2155

Source DB:  PubMed          Journal:  World J Hepatol


  35 in total

1.  Leptin and liver fibrosis: a matter of fat.

Authors:  Fabio Marra
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening.

Authors:  Albert C Y Chan; Ronnie T P Poon; Kelvin K C Ng; Chung Mau Lo; Sheung Tat Fan; John Wong
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

4.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.

Authors:  Paolo Sorrentino; Salvatore D'Angelo; Umberto Ferbo; Pietro Micheli; Alessandra Bracigliano; Raffaela Vecchione
Journal:  J Hepatol       Date:  2008-11-14       Impact factor: 25.083

Review 8.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.

Authors:  Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

9.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  20 in total

Review 1.  Environmental health in the biology century: Transitions from population to personalized prevention.

Authors:  John D Groopman
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-20

2.  Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Yvonne Huber; Christian Labenz; Maurice Michel; Marcus-A Wörns; Peter R Galle; Karel Kostev; Jörn M Schattenberg
Journal:  Dtsch Arztebl Int       Date:  2020-10-23       Impact factor: 5.594

3.  2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2016-12-16       Impact factor: 2.967

4.  Soy protein isolate inhibits hepatic tumor promotion in mice fed a high-fat liquid diet.

Authors:  Kelly E Mercer; Casey F Pulliam; Kim B Pedersen; Leah Hennings; Martin Jj Ronis
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

Review 5.  Past, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells.

Authors:  Chang-Nim Im
Journal:  Cell Stress Chaperones       Date:  2016-04-12       Impact factor: 3.667

6.  Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

Authors:  Özlem Akdoğan; Ayşegül Atak Yücel; Zeynep Gök Sargin; Cemile Sönmez; Güldal Esendağli Yilmaz; Seren Özenirler
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

7.  Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells.

Authors:  Minqian Shen; Haifei Shi
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

Review 8.  Hepatocellular carcinoma: a clinical and pathological overview.

Authors:  Salvatore Lorenzo Renne; Samantha Sarcognato; Diana Sacchi; Maria Guido; Massimo Roncalli; Luigi Terracciano; Luca Di Tommaso
Journal:  Pathologica       Date:  2021-06

Review 9.  Iron and non-alcoholic fatty liver disease.

Authors:  Laurence J Britton; V Nathan Subramaniam; Darrell Hg Crawford
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

10.  The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment.

Authors:  Encheng Yang; Xiao Li; Ningyi Jin
Journal:  Cancer Cell Int       Date:  2016-10-13       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.